Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment

E. Roekevisch (Lead / Corresponding author), M. M. G. Leeflang, M. E. Schram, L. E. Campbell, W. H. Irwin McLean, S. Kezic, J. D. Bos, P. I. Spuls, M. A. Middelkamp-Hup

Research output: Contribution to journalLetter

1 Citation (Scopus)
88 Downloads (Pure)

Abstract

Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.((1)) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved.

Original languageEnglish
Pages (from-to)1745-1746
Number of pages2
JournalBritish Journal of Dermatology
Volume177
Issue number6
Early online date19 Nov 2016
DOIs
Publication statusPublished - 8 Jan 2018

Fingerprint

Atopic Dermatitis
Immunosuppressive Agents
Mutation
Randomized Controlled Trials
Therapeutics
Azathioprine
Mouth Mucosa
Random Allocation
Methotrexate
Genotype
filaggrin

Keywords

  • Atopic dermatitis
  • Atopic eczema
  • Filaggrin
  • Skin barrier
  • Mutation
  • Azathioprine
  • Methotrexate
  • Immunosuppressive treatment
  • Treatment outcome

Cite this

Roekevisch, E. ; Leeflang, M. M. G. ; Schram, M. E. ; Campbell, L. E. ; Irwin McLean, W. H. ; Kezic, S. ; Bos, J. D. ; Spuls, P. I. ; Middelkamp-Hup, M. A. / Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment. In: British Journal of Dermatology. 2018 ; Vol. 177, No. 6. pp. 1745-1746.
@article{fd20c00da1f74c629590ed3e8ad690ff,
title = "Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment",
abstract = "Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.((1)) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86{\%}) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved.",
keywords = "Atopic dermatitis, Atopic eczema, Filaggrin, Skin barrier, Mutation, Azathioprine, Methotrexate, Immunosuppressive treatment, Treatment outcome",
author = "E. Roekevisch and Leeflang, {M. M. G.} and Schram, {M. E.} and Campbell, {L. E.} and {Irwin McLean}, {W. H.} and S. Kezic and Bos, {J. D.} and Spuls, {P. I.} and Middelkamp-Hup, {M. A.}",
note = "This article is protected by copyright. All rights reserved.",
year = "2018",
month = "1",
day = "8",
doi = "10.1111/bjd.15191",
language = "English",
volume = "177",
pages = "1745--1746",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley",
number = "6",

}

Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment. / Roekevisch, E. (Lead / Corresponding author); Leeflang, M. M. G.; Schram, M. E.; Campbell, L. E.; Irwin McLean, W. H.; Kezic, S.; Bos, J. D.; Spuls, P. I.; Middelkamp-Hup, M. A.

In: British Journal of Dermatology, Vol. 177, No. 6, 08.01.2018, p. 1745-1746.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment

AU - Roekevisch, E.

AU - Leeflang, M. M. G.

AU - Schram, M. E.

AU - Campbell, L. E.

AU - Irwin McLean, W. H.

AU - Kezic, S.

AU - Bos, J. D.

AU - Spuls, P. I.

AU - Middelkamp-Hup, M. A.

N1 - This article is protected by copyright. All rights reserved.

PY - 2018/1/8

Y1 - 2018/1/8

N2 - Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.((1)) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved.

AB - Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.((1)) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved.

KW - Atopic dermatitis

KW - Atopic eczema

KW - Filaggrin

KW - Skin barrier

KW - Mutation

KW - Azathioprine

KW - Methotrexate

KW - Immunosuppressive treatment

KW - Treatment outcome

U2 - 10.1111/bjd.15191

DO - 10.1111/bjd.15191

M3 - Letter

VL - 177

SP - 1745

EP - 1746

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 6

ER -